INTRODUCTION

The World Cancer Research Fund/ American Institute for Cancer Research: (WCRF/AICR) has been a global leader in elucidating the relationship between food, nutrition, physical activity and cancer. The First and Second Expert Reports (1;2) represent the most extensive analyses of the existing science on the subject to date.

The Second Expert Report features eight general and two special recommendations based on solid evidence which, when followed, will be expected to reduce the incidence of cancer. More recently, empirical evidence from a large European cohort study showed that people with lifestyle in agreement with the WCRF/AICR recommendations experienced decreased risk of cancer after an average follow-up time of ten years (3). The main risk reductions were for cancers of the colon and rectum, and oesophageal cancer, and significant associations were observed for cancers of the breast, endometrium, lung, kidney, upper aerodigestive tract, liver, and oesophagus.

The Second Expert Report was informed by a process of seventeen systematic literature reviews (SLRs) all of the evidence published. To keep the evidence current and updated into the future, WCRF/AICR is undertaking the Continuous Update Project (CUP) in collaboration with Imperial College London (ICL). The CUP [http://www.wcrf.org/cancer_research/cup/index.php] is an on-going systematic literature review on food, nutrition, physical activity and body fatness, and cancer risk. The project ensures that the evidence, on which the WCRF/AICR recommendations are based, continues to be the most-up-to-date and comprehensive available.

WCRF/AICR has convened a panel of experts for the CUP consisting of leading scientists in the field of diet, physical activity, obesity and cancer, who will consider the evidence produced by the systematic literature reviews conducted by the research team at ICL. The CUP Panel will judge the evidence, draw conclusions and make recommendations for cancer prevention. The entire CUP process will provide an impartial analysis and interpretation of the data as a basis for reviewing and where necessary revising the 2007 WCRF/AICR's cancer prevention recommendations (Figure 1).
The CUP builds on the foundations of the Second Expert Report to ensure a consistent approach to reviewing the evidence (4). A team at ICL conducts the CUP SLRs, where a central database has been created by merging the cancer-specific databases generated in the 2007 SLR’s. A key step of the CUP is the update of the central database with the results of randomised controlled trials and prospective studies. The CUP Expert Panel advised that these are the study designs that should be prioritized for update because the 2007 WCRF recommendations had been mainly based on the results of randomised controlled trials and prospective cohort studies.

The WCRF database is being updated at ICL in a rolling programme. The CUP started in 2007 and breast cancer was the first cancer to be updated, followed by prostate and colorectal cancers. When a cancer site is included in the CUP, the team at ICL keeps updating the database for that cancer and all the other cancers already included in the CUP (Figure 2). Currently, the central database is being updated for cancers of the breast, prostate, colon and rectum, pancreas, ovary, endometrium, bladder, kidney, gallbladder, liver and stomach.

Periodically, the CUP team at ICL prepares SLR reports with updated meta-analyses by request of the CUP Panel and Secretariat. The protocols and reports of systematic literature reviews by the IC team are available at http://www.dietandcancerreport.org/cancer_resource_center/continuous_update_project.php.

The present document is the protocol for the continuous update and the SLR on food, nutrition, physical activity and the risk of oesophageal cancer. The peer-reviewed protocol will represent the agreed plan. Should departure from the agreed plan be considered necessary at a later stage, the CUP Expert Panel must agree this and the reasons be documented.
Figure 2. The Continuous Update Project-rolling programme
Oesophageal cancer is the eight most common incident cancer worldwide and the sixth most common cause of death from cancer (Figure 3). There is a substantial racial and gender disparity in the incidence of oesophageal cancer; the incidence is approximately six to eight fold greater in men than in women, and in United States, it is four times higher in whites than in African Americans (5).

Figure 3. Estimated age (world)-standardized incidence and mortality rates by sex of selected cancers (per 100 000). World. 2008

The incidence of oesophageal cancer and the distribution of cases according to the main histological types - squamous cell carcinoma (SCC) and adenocarcinoma- vary throughout regions of the world. Before the 1970s, SCC constituted over 90% of all oesophageal cancer cases worldwide. However, the incidence rates of oesophageal adenocarcinoma have sharply increased and now it constitutes approximately half of all oesophageal cancer cases in many Western countries. A rapid increase in the prevalence of Barrett’s oesophagus, a condition that confers about a 100-fold increased risk of developing oesophageal adenocarcinoma (EAC), has also been
documented (6). SCC continue to be the most frequent histological type found in people living in the area from northeast China to north central Asia, Afghanistan and northern Iran (the ‘Asian Oesophageal Cancer Belt’). Other high-risk areas are Eastern Sub-Saharan Africa and some areas of Finland, Iceland, and France (Figure 4) (5).

Figure 4. Estimated age-standardized incidence of oesophageal cancer (per 100 000). World 2008

Estimated age-standardised incidence rate per 100,000

Oesophagus: both sexes, all ages

The role of genetic factors in oesophageal cancer is not clear. Given the changes in the incidence rate in different geographic areas, it is likely that lifestyle and other environmental factors play important roles along with genetic factors. A number of studies have demonstrated a positive dose-response relationship of squamous cell oesophageal cancer risk with alcohol consumption and cigarette smoking (7-9) and an increased risk in relation of poor oral health and exposure to human papillomavirus whereas tobacco smoking and, probably, absence of H pylori in the stomach may increase the risk of oesophageal adenocarcinoma (10).
The expert panel of the WCRF/AICR Second Report (1) concluded that the evidence that body fatness increases the risk of adenocarcinoma of the oesophagus and that alcohol drinking increases the risk of oesophageal cancer was convincing. There was no other “convincing” evidence of an association of food, nutrition and physical activity with oesophageal cancer risk. The panel considered that the evidence supported that fruits, non-starchy vegetables, foods containing β-carotene, and vitamins C were “probably” protective against the risk of oesophageal cancer, while the evidence on a role of foods containing fibre, folate, pyridoxine and vitamin E was judged as “limited evidence” of a protective effect. The panel also concluded that drinking maté probably increases oesophageal cancer risk, while the evidence on a role of red meat and processed meat was judged as “limited evidence” of an increased risk (Figure 5). Since the number of studies was limited, the Panel could not evaluate risk factors separately for squamous cell carcinoma and adenocarcinoma of the oesophagus.
Figure 5. Summary of judgements of the 2007 Second Expert Report on oesophageal cancer 2007 (1)

<table>
<thead>
<tr>
<th></th>
<th>DECREASES RISK</th>
<th>INCREASES RISK</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Convincing</strong></td>
<td></td>
<td>Alcoholic drinks</td>
</tr>
<tr>
<td></td>
<td>Body fatness</td>
<td>Maté</td>
</tr>
<tr>
<td><strong>Probable</strong></td>
<td>Non-starchy vegetables</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fruits</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Foods containing beta-carotene</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Foods containing vitamin C</td>
<td></td>
</tr>
<tr>
<td><strong>Limited — suggestive</strong></td>
<td>Foods containing dietary fibre</td>
<td>Red meat</td>
</tr>
<tr>
<td></td>
<td>Folate</td>
<td>Processed meat</td>
</tr>
<tr>
<td></td>
<td>Foods containing pyridoxine</td>
<td>High-temperature drinks</td>
</tr>
<tr>
<td></td>
<td>Foods containing vitamin E</td>
<td></td>
</tr>
<tr>
<td><strong>Limited — no conclusion</strong></td>
<td>Cereals (grains) and their products; starchy roots, tubers, and plantains; pulses (legumes); soya and soya products; herbs, spices, and condiments; poultry; fish; eggs; milk and dairy products; total fat; saturated fatty acids; monounsaturated fatty acids; polyunsaturated fatty acids; sugary foods and drinks; salt; salting; fermenting; pickling; smoked and cured foods; nitrates and nitrites; frying; grilling (broiling) and barbecuing (charbroiling); protein; vitamin A; retinol; thiamin; riboflavin; calcium; iron; zinc; pro-vitamin A carotenoids; beta-cryptoxanthin; Seventh-day Adventist diets; adult attained height; energy intake</td>
<td>None identified</td>
</tr>
</tbody>
</table>

1 For oesophageal adenocarcinomas only.
2 Judgements on vegetables and fruits do not include those preserved by salting and/or pickling.
3 Includes both foods naturally containing the constituent and foods which have the constituent added (see chapter 3.5.3). Dietary fibre is contained in plant foods (see box 4.1.2 and chapter 4.2).
4 As drunk traditionally in parts of South America, scalding hot through a metal straw. Any increased risk of cancer is judged to be caused by epithelial damage resulting from the heat, and not by the herb itself.
5 Vitamin B6.
6 The term ‘red meat’ refers to beef, pork, lamb, and goat from domesticated animals.
7 The term ‘processed meat’ refers to meats preserved by smoking, curing, or salting, or addition of chemical preservatives.

For an explanation of all the terms used in the matrix, please see chapter 3.5.1, the text of this section, and the glossary.

Note: The number of studies was limited and the Panel could not evaluate risk factors separately for squamous cell carcinoma and adenocarcinoma of the oesophagus
1. RESEARCH QUESTION

The research topic is:
The associations between food, nutrition and physical activity and the risk of oesophageal squamous cell carcinomas and oesophageal adenocarcinomas.

The main objective is:
To summarize the evidence from prospective studies and randomised controlled trials on the association between foods, nutrients, physical activity, body adiposity and the risk of oesophageal squamous cell carcinomas and oesophageal adenocarcinomas in men and women.

2. REVIEW TEAM

<table>
<thead>
<tr>
<th>Name</th>
<th>Current position at IC</th>
<th>Role within team</th>
</tr>
</thead>
<tbody>
<tr>
<td>Teresa Norat</td>
<td>Principal Research Fellow</td>
<td>Principal investigator</td>
</tr>
<tr>
<td>Doris Chan</td>
<td>Research Assistant</td>
<td>Supervisor of data extraction. Data analyst, SLR report preparation</td>
</tr>
<tr>
<td>Ana Rita Vieira</td>
<td>Research Assistant</td>
<td>Data analyst, SLR report preparation</td>
</tr>
<tr>
<td>Leila Abar</td>
<td>Research Assistant</td>
<td>Systematic search, article selection, data extraction</td>
</tr>
<tr>
<td>Deborah Navarro</td>
<td>Research Assistant</td>
<td>Systematic search, article selection, data extraction</td>
</tr>
<tr>
<td>Snieguole Vingeliene</td>
<td>Research Assistant</td>
<td>Systematic search, article selection, data extraction</td>
</tr>
</tbody>
</table>

Review coordinator, WCRF: Rachel Thompson
Statistical advisor: Darren Greenwood, senior Research Lecturer, University of Leeds

All the reviewers are trained in the procedures for literature search, data selection and extraction for systematic literature reviews. The reviewers that will conduct the data analyses have experience in meta-analyses. Selected SLRs published by members of the ICL team are in the References Section (11-23).
3. TIMELINE

The SLRs for the Second Expert Report ended in December 30th 2005. The SLR centre extracted all the data from relevant articles published up to this date for the Second Expert Report.

The CUP team at IC will search and extract data of the articles from prospective studies and randomised controlled trials published from January 1st 2006. The reviewers will verify that there are not duplicities in the database using a module for article search implemented in the interface for data entry.

List of tasks and deadlines for the continuous update on oesophageal cancer:

<table>
<thead>
<tr>
<th>Task</th>
<th>Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Start Medline search of relevant articles published from January 1st 2006</td>
<td>March 1, 2013</td>
</tr>
<tr>
<td>Start review of title and abstracts of articles identified in electronic search and select papers for complete review</td>
<td>March 15, 2013</td>
</tr>
<tr>
<td>Download papers and select relevant papers for data extraction</td>
<td>March 28, 2013</td>
</tr>
<tr>
<td>Start data extraction</td>
<td>April 15, 2013</td>
</tr>
<tr>
<td>Start hand search of references</td>
<td>April 15, 2013</td>
</tr>
<tr>
<td>Start quantitative analysis of articles included in PubMed up to 30th May 2014*</td>
<td>July 1, 2014</td>
</tr>
<tr>
<td>Start writing SLR report</td>
<td>July 1, 2014</td>
</tr>
<tr>
<td>Send SLR report for review to CUP secretariat</td>
<td>October 30, 2014</td>
</tr>
<tr>
<td>Review and modify SLR report according to reviewer’s comments</td>
<td>January 2015</td>
</tr>
<tr>
<td>Send reviewed SLR report to CUP secretariat</td>
<td>January 31, 2015</td>
</tr>
<tr>
<td>Transfer Endnote files to SLR CUP Secretariat</td>
<td>February 28, 2015</td>
</tr>
<tr>
<td>Panel meeting</td>
<td>June 2015</td>
</tr>
</tbody>
</table>

*End date of the intermediate systematic literature review to the CUP Panel

4. SEARCH STRATEGY

4.1. Search database

The Medline database (includes coverage from 70 countries) will be searched using PubMed as platform. The rationale for searching only in Medline is that the results of the SLR’s for the Second Expert Report indicated that searching reports of prospective studies in databases other than Medline was not cost effective (24). Central and ClinicalTrials.gov will be searched for evidence of trials relevant to this review.

4.2. Hand searching for cited references

The review team will also hand search the references of reviews and meta-analyses identified during the search.

4.3 Search strategy for PubMed

9
The CUP review team will use the search strategy established in the SLR Guidelines for the WCRF-AICR Second Expert Report (24). A first search will be conducted using as date limits January 1st 2006 to February 28th 2013 and subsequent searches will be conducted every month.

The search will be conducted in three steps:

1) Searching for studies relating to food, nutrition and physical activity
2) Searching for studies relating to oesophageal cancer
3) Searching for studies relating food, nutrition and physical activity, and oesophageal cancers

The full search strategy is in Annex 1.

5. STUDY SELECTION CRITERIA FOR THE UPDATE

5.1 Inclusion criteria

The articles to be included in the review:

- Must have as exposure/intervention: dietary patterns, foods, nutrients –dietary, supplemental or both-, diet biomarkers, indicators of body adiposity in early life, adolescence or adulthood, changes in body adiposity, height, and breastfeeding.
- Must have as outcome of interest incidence or mortality of oesophageal cancer
- Included in Medline from January 1st 2006
- Have to present results from an epidemiologic study in men and/or women of one of the following types:
  - Randomized controlled trial
  - Group randomized controlled trial (Community trial)
  - Prospective cohort study
  - Nested case-control study
  - Case-cohort study
  - Historical cohort study
- In individuals free of cancer at the moment of exposure assessment or intervention (except non melanoma skin cancer)

\* Articles identified in the search with the following outcomes: “gastro-oesophageal” cancer, “upper aero-digestive cancers” and other cancers groups that explicitly includes oesophageal cancer will also be extracted. The cancers group name will be indicated in the database under “cancer type” and the description of the cancers included in the identified groups will be indicated under “cancer type description”.

\footnote{January 1st 2006 is the closure date of the database for the Second Expert Report.}

5.2 Exclusion criteria
• Cohort studies in which the only measure of the relationship between the relevant exposure and outcome is the mean difference of exposure (this is because the difference is not adjusted for main confounders).
• Articles in foreign language that cannot be translated (members in the review team can read Chinese, French, Italian, Spanish and Portuguese).

6. ARTICLE SELECTION
First, all references obtained with the searches in PubMed will be imported in a Reference Manager Database using the filter Medline.

The article selection will follow three steps:
1. An electronic search will first be undertaken within Reference Manager to facilitate the identification of irrelevant records by using the terms indicated below. Relevance will be assessed upon reading of the titles and abstracts of the articles identified by the electronic search.

List of terms for use within Reference Manager Database

Radiotherapy
Chemotherapy
Cisplatinum
Docetaxel
Cell
Inhibitor
Novel
Model
Receptor
Antibody
Transgenic
Mice
Hamster
Rat
Dog
Cat
In vitro

2. In a second step, two reviewers will assess the titles and abstracts of the remaining articles.

3. In a third step, the reviewers will assess the full manuscripts of all papers for which eligibility could not be determined by reading the title and abstract.

The reviewers will solve any disagreements about the study or exposure relevance by discussion with the principal investigator.

6.1 Reference Manager Files
Five user-defined fields (Table 1) will be created in the Reference Manager database where the reviewers will indicate:
1) if the study was selected upon reading of title and abstract, or entire article
2) the study design of articles on exposures/interventions and outcome relevant to the review
3) the status of data extraction of included articles
4) the WCRF code assigned to included studies during data extraction
5) reasons for exclusion of articles on exposures/interventions and outcome relevant to the review

Table 1. User-defined fields and terms to be used in the Reference Manager database for identification of the status of articles identified in the searches

<table>
<thead>
<tr>
<th>Field</th>
<th>Use</th>
<th>Terms</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>User Def 1</td>
<td>Indicate result of assessment for inclusion</td>
<td>Excludedabti</td>
<td>Excludedabti: paper exclusion based on abstract and title</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Excluded</td>
<td>Excluded: paper exclusion based on full paper text</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Included</td>
<td>Included: reports of case-control studies, cohort studies, pooled analysis and trials relevant to the review.</td>
</tr>
<tr>
<td>User Def 2</td>
<td>Reasons for exclusion</td>
<td>No measure of association</td>
<td>No original data uses data from others</td>
</tr>
<tr>
<td></td>
<td></td>
<td>No original data</td>
<td>No adequate study design includes non-controlled trials, cross-sectional analysis, ecological studies.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Commentary, no original data</td>
<td>Already extracted refers to studies identified by another search</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Foreign article in [language]</td>
<td>Cancer survivors for studies that are not in people free of cancer at baseline</td>
</tr>
<tr>
<td></td>
<td></td>
<td>No adequate study design</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Meta-analysis</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Already extracted</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cancer survivors</td>
<td></td>
</tr>
<tr>
<td>User Def 3</td>
<td>Study design</td>
<td>Randomized controlled trial (RCT)</td>
<td>Case-control study-other: when the comparison populations are neighbors, friends, and any other case in which the controls are not population- or hospital-based.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prospective cohort study</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Retrospective cohort study</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nested case-control study</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Case cohort study</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Population-based case-control study</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hospital-based case-control study</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Case-control study- other</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pooled analysis of cohort</td>
<td></td>
</tr>
</tbody>
</table>
7. DATA EXTRACTION

The IC team will update the WCRF-AICR central database using an interface created or this purpose (Figure 6). The application will automatically check that the paper has not already been extracted to the database using author name, publication year and journal references. The data extracted will be double-checked by a second reviewer.

The data to be extracted include study design, name, characteristics of study population, mean age, distribution by sex, country, recruitment year, methods of exposure assessment, definition of exposure, definition of outcome, method of outcome assessment, study size, length of follow up, lost to follow-up, analytical methods and whether methods for correction of measurement error were used.

The ranges, means or median values for each level of the exposure will be extracted as reported in the paper. For each result, the reviewers will extract the covariates included in the analytical models and the matching variables. Measures of association, number of cases and number of comparison individuals or person years for each category of exposure will be extracted for each model used in the analyses as reported in the papers. The reviewer will not do any calculation during this phase. Stratified and subgroup analyses, and results of interaction analyses will be extracted (e.g. by sex, age group, smoking status, BMI category, alcohol intake level, etc.)

The reviewer should extract the results for each histological type of cancer (SCC or adenocarcinoma). Results on “oesophageal cancer” without indication of histological type will be extracted as a separate category, as well as the results for any other cancer group that includes oesophageal cancer (e.g. gastro-oesophageal cancer, upper aero-digestive tract, other).

The reviewer will also extract all the associations observed in stratified or interaction analyses in the paper,
7.1 Allocation of study design

The study design algorithm devised for use of the SLR centres for the Second Expert Report will be used to allocate study designs to papers. In some cases, it will be appropriate to assign more than one design to a particular paper (e.g. analyses in the entire cohort and nested case-control). The algorithm is in Figure 7.
Figure 7. Study design algorithm (From: SLR specification manual)

Key to study design algorithm
Study design A Case-study / case series
Study design B Cross-sectional study
Study design C Randomised controlled trial
Study design D Group randomized control trial
Study design E Uncontrolled trial
Study design F Ecologic study
Study design G Case-control study
Study design H Non-randomized control trial
Study design J Prospective cohort study
Study design K Nested case-control study
Study design L Historical cohort study
Study design M Case-cohort study
Study design N Time series with multiple measurements
Study design P Case only study with prospective exposure measurement
Study design Q Case only study with retrospective exposure measurement
7.2 Study identifier
The CUP team will use the same labelling of articles used in the SLR process for the Second Expert Report: the unique identifier for an article will be constructed using a 3-letter code to represent the cancer site: OES (oesophageal cancer), followed by a 5-digit number that will be generated sequentially by the software during data extraction.

7.3 Codification of exposures/interventions.
The exposures/interventions will be codified during data extraction as in the Second Expert Report. The main headings and sub-headings codes are in Annex 2. Wherever possible, the reviewer will use the sub-heading codes. Additional codes have been programmed in the database to facilitate the data entry.

The reviewer should also extract the description of the exposure/intervention definition in the free text box provided for that purpose in the data entry screen. The definition will be extracted as it appears in the paper.

The main headings for codification of the exposure groups are:

1. **Patterns of diet**, includes regionally defined diets, socio-economically defined diets, culturally defined diets, individual level dietary patterns, other dietary patterns, breastfeeding and other issues
2. **Foods**, including starchy foods; fruit and (non-starchy) vegetables; pulses (legumes); nuts and seeds; meat, poultry, fish and eggs; fats, oils and sugars; milk and dairy products; and herbs, spices, and condiments, and composite foods.
3. **Beverages**, including total fluid intake, water, milk, soft drinks, fruit juices, hot drinks and alcoholic drinks.
4. **Food production** including traditional methods and chemical contaminants, food preservation, processing and preparation.
5. **Dietary constituents**, including carbohydrate, lipids, protein, alcohol, vitamins, minerals, phytochemicals, nutrient supplements and other bioactive compounds
6. **Physical activity**, including total physical activity, physical inactivity and surrogate markers for physical activity.
7. **Energy balance**, including energy intake, energy density and energy expenditure.
8. **Anthropometry**, including markers of body composition, markers of body fat distribution, height and other skeletal measures, and growth in foetal life, infancy or childhood.

7.3.1 Codification of biomarkers of exposure
Biomarkers of exposure will be included under the heading and with the code of the corresponding exposure.

During the SLR for the Second Expert Report, some review centres opted for including in the review only biomarkers for which there was strong evidence on reliability or validity whereas other centres opted for including results on all the biomarkers retrieved in the search, independently of their validity. For the evaluation of the evidence, the Panel of Experts took in consideration the validity of the reported biomarkers.
However, since the identification and validation of other biomarkers is an expanding area in nutritional epidemiology (25), the CUP team will extract the data for all biomarkers of intake reported in the studies, independently of whether validity and reliability had been or not fully documented.

7.4 Codification of outcomes.

The reviewer will indicate in the field: outcome type, whether the outcome is incidence or mortality and in outcome subtype, if the results are on oesophageal adenocarcinoma, squamous cell carcinoma or oesophageal cancer not specified.

7.5 Extraction and labelling of study results

The reviewer will extract the measures of association (RR estimates and confidence intervals) for the relevant exposures from all the statistical models shown in the paper, including subgroups, stratified analyses, interactions and sensitivity analyses. These results are shown in the paper in tables, in the text or as supplemental information.

The reviewer should label the results as unadjusted, intermediately adjusted, or most adjusted model, depending of the models:

- The results of univariate models will be labelled “unadjusted”.
- The results obtained with the model including the higher number of covariates in the article will be labelled “most adjusted”.
- The results obtained using any multivariable model that is not the most adjusted model will be labelled “intermediately” adjusted.

In addition, the reviewer will indicate the “best model” for meta-analyses.

The “best” model will be selected using two criteria: level of control for confounding and completeness of the data for dose-response meta-analysis. The best model will be the most adjusted model in the article.

Sometimes, the researchers use models that include variables likely to be in the causal pathway with the purpose of exploring hypothetical mechanisms. When “mechanistic” models are reported by the authors, the “intermediately” adjusted result with the highest number of covariates will be indicated as “best model”. The mechanism models will be extracted and labelled as most adjusted model, but not as best model for meta-analysis. If there are enough results with these models, they can be used in separate analysis.

In addition to adjustment, other criteria to consider for identifying the ‘best model’ for meta-analysis are the completeness of the data (e.g. the most adjusted does not provide all the data needed or the information to compute missing values but the data of the less adjusted model is more complete). In such situations, a model that is not the most adjusted model will be identified as “best model” for meta-analyses.
8. QUALITY CONTROL OF THE ARTICLE SELECTION AND DATA EXTRACTION.

A second reviewer at ICL will check the article selection and the data extraction. If there are discrepancies between the reviewers, the discrepancy will be discussed with the Principal Investigator.

9. DATA ANALYSIS

9.1 Meta-analysis

The CUP team at IC will update the meta-analyses conducted for the Second Report. The CUP SLR will not conduct meta-analysis using as contrast the highest vs. the lowest category of exposure/intervention except when most of the papers identified have categorised participants in two groups (e.g. breastfeeding categorised as yes vs. no, use of multivitamins categorised as yes vs. no) and for physical activity because usually quantitative levels are not provided.

Meta-analyses will be conducted for oesophageal squamous cell carcinoma and for adenocarcinomas. Studies on oesophageal cancer with histology not specified will be analysed separately.

The meta-analyses will be conducted for studies on incidence and mortality as outcome separately and combined.

Studies on cancers with different anatomical localisations (for example, gastro-oesophageal cancers) will not be pooled together with those of oesophageal cancer.

Where results from two or three cohort studies are reported in the same paper, the results of each cohort will be included separately in the CUP meta-analysis instead of using the pooled result reported in the paper. The purpose is to look at heterogeneity across study results. The same will be done for the results of pooling projects or consortia.

Sensitivity analyses will be conducted including the overall results of pooling projects or cohort consortia identified. The same study will not be included twice in one meta-analysis.

The results of the individual studies will be displayed graphically in forests plots of the highest vs. the lowest comparison for each study, but a summary estimate will not be calculated, to avoid pooling different exposure levels. In all forest plots, the studies will be ordered by publication year, with the most recent on the top.

Linear dose-response meta-analysis will be conducted to express the results of each study in the same increment unit for a given exposure and the results will be shown in a dose-response forest plot. For comparability, the increment units for the linear dose-response analyses will be those used in the meta-analyses in the previous SLRs (Table 2) but another increment may have to be used in the range of exposure in the identified papers is smaller than the recommended increment unit. If most of the identified studies report servings, times, units these will be used as increment unit.

Non-linear dose-response meta-analyses will be conducted as exploratory analysis.
### Table 2. Recommended increment units for meta-analyses.

<table>
<thead>
<tr>
<th>Exposure</th>
<th>Increment unit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total fruits and vegetables</td>
<td>100 g</td>
</tr>
<tr>
<td>Non starchy vegetables</td>
<td>100 g</td>
</tr>
<tr>
<td>Fruits</td>
<td>100 g</td>
</tr>
<tr>
<td>Citrus fruits</td>
<td>50 g</td>
</tr>
<tr>
<td>Red meat</td>
<td>100 g</td>
</tr>
<tr>
<td>Processed meat</td>
<td>50 g</td>
</tr>
<tr>
<td>Poultry</td>
<td>100 g</td>
</tr>
<tr>
<td>Fish</td>
<td>50 g</td>
</tr>
<tr>
<td>Eggs</td>
<td>25 g</td>
</tr>
<tr>
<td>Salt</td>
<td>1 g</td>
</tr>
<tr>
<td>Coffee</td>
<td>1 cup</td>
</tr>
<tr>
<td>Tea</td>
<td>1 cup</td>
</tr>
<tr>
<td>Alcoholic drinks</td>
<td>1 drink/day</td>
</tr>
<tr>
<td>Alcohol (as ethanol)</td>
<td>10 g</td>
</tr>
<tr>
<td>Dietary calcium</td>
<td>200 mg</td>
</tr>
<tr>
<td>Dietary fibre</td>
<td>10 g</td>
</tr>
<tr>
<td>Folate</td>
<td>100 µg</td>
</tr>
<tr>
<td>Blood selenium</td>
<td>10 µg/L</td>
</tr>
<tr>
<td>Beer</td>
<td>10 g/day (approx. one drink)</td>
</tr>
<tr>
<td>Wine</td>
<td>10 g/day (approx. one drink)</td>
</tr>
<tr>
<td>BMI</td>
<td>5 kg/m$^2$</td>
</tr>
<tr>
<td>Waist</td>
<td>2.5 cm (1 inch)</td>
</tr>
<tr>
<td>Waist-to-hip</td>
<td>0.1 unit</td>
</tr>
<tr>
<td>Height</td>
<td>5 cm</td>
</tr>
<tr>
<td>Physical activity</td>
<td>5 MET-h per week</td>
</tr>
</tbody>
</table>

#### 9.2 Selection of exposures for a dose-response meta-analysis

The meta-analysis will include studies identified during the SLR and studies identified during the CUP.

A dose-response meta-analysis will be conducted when at least two new reports of trials or two news reports or cohort studies with enough data for dose-response meta-analysis are identified during the CUP and if the total number of studies to be included is at least of 5 in each study design, or if there is a pooling project or consortium of studies published. The minimum number of two studies was not derived statistically but it is a number of studies that can be reasonable expected to have been published after the Second Expert Report.

Where a particular study has published more than one paper on the same exposure, the analysis using the larger number of cases will be selected but if the most recent paper does not provide enough information for the dose-response meta-analysis, the previous publication with the required information will be used. The results section will indicate whether the reports of the same study are similar or not.
9.3 Selection of results for meta-analyses

The results based on “best” adjusted models will be used in the dose-response meta-analyses. When the linear dose-response estimate is reported in an article, this will be used in the CUP dose-response meta-analysis. If the results are presented only for categorical exposures/intervention (quantiles or pre-defined categories), the slope of the dose-response relationship for each study will be derived from the categorical data.

9.4 Derivation of data required for meta-analyses.

The data required to derive the dose-response slope from categorical data are:

1. number of cases for each exposure category
2. person-years -or number of comparison individuals nested case-control analyses- for each exposure category
3. median, mean or cut-offs of exposure categories.

The information provided in the articles is often incomplete and this may result in exclusions of results from meta-analyses. In the SLR on oesophageal and prostate cancers for the Second Expert Report, only 64% of the cohort studies provided enough data to be included in dose-response meta-analysis, and there was empirical evidence that studies that showed an association were more likely to be usable in dose-response meta-analysis than studies that did not show any evidence (26).

The failure to include all available evidence will reduce precision of summary estimates and may also lead to bias if propensity to report results in sufficient detail is associated with the magnitude and/or direction of associations. To address the data incompleteness, a number of approaches will be undertaken to derive the missing data from the available data where possible (26). The approaches are summarized in Table 3.
<table>
<thead>
<tr>
<th>Type of data</th>
<th>Problem</th>
<th>Approach</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose-response data</td>
<td>Serving size is not quantified or ranges are missing, but group descriptions are given</td>
<td>Use serving size recommended in SLR</td>
</tr>
<tr>
<td></td>
<td>Standard error missing</td>
<td>The p value (either exact or the upper bound) is used to estimate the standard error</td>
</tr>
<tr>
<td>Quantile-based data</td>
<td>Numbers of controls (or the denominator in cohort studies) are missing</td>
<td>Group sizes are assumed to be approximately equal</td>
</tr>
<tr>
<td></td>
<td>Confidence interval is missing</td>
<td>Use raw numbers of cases and person years (or controls in nested case-control studies) to calculate confidence interval (although doing so may result in a somewhat smaller standard error than would be obtained in an adjusted analysis)</td>
</tr>
<tr>
<td></td>
<td>Group mean are missing</td>
<td>This information may be estimated by using the method of Chêne and Thompson (27) with a normal or lognormal distribution, as appropriate, or by taking midpoints (scaled in unbounded groups according to group numbers) if the number of groups is too small to calculate a distribution (3-4 groups)</td>
</tr>
<tr>
<td>Category data</td>
<td>Numbers of controls (or the denominator in cohort studies) is missing</td>
<td>Derive these numbers from the numbers of cases and the reported odds ratios (proportions will be correct unless adjustment for confounding factors considerably alter the crude odds ratios)</td>
</tr>
</tbody>
</table>

For estimating the “dose-response” for each study, means or medians of the exposure categories will be assigned as “dose” if reported in the articles; if not reported, the midpoints of the exposure range will be assigned to the relative risk of the corresponding category. For lowest or highest open-ended categories the amplitude of the nearest category will be used for the calculation of the midpoint. In cases where the units of measurement differed between results, the units would be converted, where possible. Where assumptions had to be made on portion or serving sizes the assumptions used in the WCRF/AICR Second Expert Report will be applied (4) (Table 4). For studies reporting intakes in grams/1000 kcal/day, the intake in grams/day will be estimated using the average energy intake reported in the article.
Table 4. List of conversion units

<table>
<thead>
<tr>
<th>Item</th>
<th>Conversion of one unit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beer</td>
<td>400ml serving</td>
</tr>
<tr>
<td>Cereals</td>
<td>60g serving</td>
</tr>
<tr>
<td>Cheese</td>
<td>35g serving</td>
</tr>
<tr>
<td>Dried fish</td>
<td>10g serving</td>
</tr>
<tr>
<td>Eggs</td>
<td>55g serving (1 egg)</td>
</tr>
<tr>
<td>Fats</td>
<td>10g serving</td>
</tr>
<tr>
<td>Fruit &amp; Vegetables</td>
<td>80g serving</td>
</tr>
<tr>
<td>Fruit Juice</td>
<td>125ml serving</td>
</tr>
<tr>
<td>General drinks inc. soft &amp; hot drinks</td>
<td>200ml serving</td>
</tr>
<tr>
<td>Meat &amp; Fish</td>
<td>120g serving</td>
</tr>
<tr>
<td>Milk</td>
<td>50ml serving</td>
</tr>
<tr>
<td>Milk as beverage</td>
<td>200ml serving</td>
</tr>
<tr>
<td>Processed cheese slice</td>
<td>10g serving</td>
</tr>
<tr>
<td>Processed meat</td>
<td>50g serving</td>
</tr>
<tr>
<td>Shellfish</td>
<td>60g serving</td>
</tr>
<tr>
<td>Spirits</td>
<td>25ml serving</td>
</tr>
<tr>
<td>Staple foods (rice, pasta, potatoes,</td>
<td></td>
</tr>
<tr>
<td>beans &amp; lentils, foods boiled in soy sauce</td>
<td></td>
</tr>
<tr>
<td>Water &amp; Fluid intake</td>
<td>8oz cup</td>
</tr>
<tr>
<td>Wine</td>
<td>125ml serving</td>
</tr>
</tbody>
</table>

9.5 Statistical Methods

The slopes of the dose-response relationships will be derived from categorical data using generalized least-squares for trend estimation (command GLST in Stata) (28). This method accounts for the correlation between relative risks estimates with respect to the same reference category (29). The dose-response model is forcing the fitted line to go through the origin and whenever the assigned dose corresponding to the reference group (RR=1) is different from zero, this will be rescaled to zero and the assigned doses to the other exposure categories will be rescaled accordingly.

The study specific log odds ratios per unit increase in exposure will be combined in a random effect model using the method of DerSimonian and Laird (30), with the estimate of heterogeneity being taken from the inverse-variance fixed-effect model.

Publication and related bias (e.g. small study bias) will be explored through visual examination of funnel plots and Egger’s test (31). Funnel plots will be shown when there are at least four studies included in the analysis.

Heterogeneity between studies will be quantified with the $I^2$ statistic - where cut points $I^2$ values of 30%, and 50% correspond to low, moderate, and high degrees of heterogeneity (32). Heterogeneity will be assessed visually from forest plots and with statistical tests (P value <0.05 will be considered statistically significant) but the interpretation will rely mainly in the $I^2$ values as the test has low power and the number of studies will probably be limited.

Potential sources of heterogeneity will be explored by stratified analyses when the number of studies allows it (at least two studies in each stratum). The variables that will be explored as sources of heterogeneity are oesophageal cancer histology,
outcome (incidence or mortality), gender, geographic area, level of control for confounder, publication year, length of follow-up. Meta-regression will be conducted when the number of studies allows it.

The interpretation of stratified analysis should be cautious. If a considerable number of study characteristics are investigated in a meta-analysis containing only a small number of studies, then there is a high probability that one or more study characteristics will be found to explain heterogeneity, even in the absence of real associations.

Potential non-linear dose-response relationships will be explored using fractional polynomial models (33). The best fitting second order fractional polynomial regression model defined as the one with the lowest deviance will be determined. Non-linearity will be tested using the likelihood ratio test (34). These analyses will be conducted using a program in Stata prepared by D. Greenwood, statistical advisor of the project.

All analyses will be conducted in Stata/SE 12.1.

9.7 Sensitivity analyses

Sensitivity analyses will be carried out to investigate how robust the overall findings of the CUP are relative to key decisions and assumptions that were made in the process of conducting the update. The purpose of doing sensitivity analyses is to strengthen the confidence that can be placed in the results.

Sensitivity analysis will be done as a minimum in the following cases:

- Including and excluding studies where there is some ambiguity as to whether they meet the inclusion criteria, for example it may be unclear what histological types are considered in a study (e.g. it is unclear if part of the cases are not of the same histology as the others)
- Including and excluding studies where exposure level was inferred by the authors (for example assigning a standard portion size when this is not provided) or other missing information was derived from the data.
- Influence-analyses where each individual study will be omitted in turn in order to investigate the sensitivity of the pooled estimates to inclusion or exclusion of particular studies (35).
- Including the results of pooling projects of cohort studies. In these analyses, the reviewer will check that studies in the pooled analyses are not included also as individual studies.

10. SYSTEMATIC LITERATURE REVIEW

An updated SLR will be sent to the CUP Secretariat on January 30, 2015 for discussion in the Expert Panel.

The SLR report will include the following elements:

1. Modifications of the approved protocol
   Any modification required during the review will be described
2. Results of the search
   Flowchart with number of records downloaded, number of papers thought potentially relevant after reading titles and abstracts and number of papers included. The reasons for excluding papers should also be described.

3. Summary tables of studies identified in the continuous update
   Number of studies by study design and publication year.
   Number of studies by exposure (main heading and selected subheadings) and publication year
   Number of studies by exposure and outcome subtype

4. Tabulation of study characteristics

   The tables will include study characteristics (e.g. population, exposure, outcome, study design) and main study results.

   The tables will include the information required by the Panel to judge the quality of the studies included in the analyses (Newcastle –Ottawa quality assessment scale (36) for cohort studies and the Cochrane Collaboration’s tool for assessing risk of bias (37)).

   Example of table of study characteristics for cohort studies (in two parts below):

<table>
<thead>
<tr>
<th>Author, Year, country, WCRF Code</th>
<th>Study design</th>
<th>Country, Ethnicity, other characteristics</th>
<th>Age (mean)</th>
<th>Cases (n)</th>
<th>Non cases (n/person-years)</th>
<th>Case ascertainment</th>
<th>Follow-up (years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assessment details</td>
<td>Category of exposure</td>
<td>Subgroup</td>
<td>No cat</td>
<td>RR</td>
<td>(95% CI)</td>
<td>p trend</td>
<td>Adjustment factors</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>A</td>
</tr>
</tbody>
</table>

10.7 Results of the dose-response meta-analysis

   Main characteristics of included and excluded studies in dose-response meta-analysis will be tabulated, and reasons for exclusions will be detailed.
The results of meta-analysis will be presented in tables and forest plots. The tables will include a comparison with the results of the meta-analyses undertaken during the SLR for the Second Expert Report.

All forest plots in the report will have the same format. Footnotes will provide quantified information (statistical tests and $I^2$ statistics) on the degree of heterogeneity between the displayed studies.

Meta-regression, stratified analyses and sensitivity analyses results will be presented in tables and, if the number of studies justifies it, in forest plots.
Reference List


Annex 1. WCRF - PUBMED SEARCH STRATEGY

1) Searching for all studies relating to food, nutrition and physical activity:

#1 diet therapy[MeSH Terms] OR nutrition[MeSH Terms]
#3 food and beverages[MeSH Terms]
#6 pesticides[MeSH Terms] OR fertilizers[MeSH Terms] OR "veterinary drugs"[MeSH Terms]
#8 food preservation[MeSH Terms]
#10 cookery[MeSH Terms]
#12 ((carbohydrates[MeSH Terms] OR proteins[MeSH Terms]) and (diet*[tiab] or food*[tiab])) OR sweetening agents[MeSH Terms]
#14 vitamins[MeSH Terms]
#16 physical fitness[MeSH Terms] OR exertion[MeSH Terms] OR physical endurance[MeSH Terms] OR walking[MeSH Terms]
#20 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19
#21 animal[MeSH Terms] NOT human[MeSH Terms]
2) Searching for all studies relating to oesophageal cancer:

#23  Esophageal Neoplasms [MeSH]
#24  Esophag*[tiab] OR oesophag*[tiab] OR upper aero digestive tract[tiab]
#26  #24 AND #25
#31  #27 OR #28 OR #29 OR #30
#32  #23 OR #26 OR #31

3) Searching for all studies relating oesophageal cancer, and food, nutrition and physical activity:

#32  #22 AND #32
Annex 2. LIST OF HEADINGS AND EXPOSURE CODES (minimum list)

*Indicates codes added during the CUP

1 Patterns of diet
1.1 Regionally defined diets
*1.1.1 Mediterranean diet

Include all regionally defined diets, evident in the literature. These are likely to include Mediterranean, Mesoamerican, oriental, including Japanese and Chinese, and “western type”.

1.2 Socio-economically defined diets

To include diets of low-income, middle-income and high-income countries (presented, when available in this order). Rich and poor populations within low-income, middle-income and high-income countries should also be considered. This section should also include the concept of poverty diets (monotonous diets consumed by impoverished populations in the economically-developing world mostly made up of one starchy staple, and may be lacking in micronutrients).

1.3 Culturally defined diets

To include dietary patterns such as vegetarianism, vegan diets, macrobiotic diets and diets of Seventh-day Adventists.

1.4 Individual level dietary patterns

To include work on factor and cluster analysis, and various scores and indexes (e.g. diet diversity indexes) that do not fit into the headings above.

1.5 Other dietary patterns

Include under this heading any other dietary patterns present in the literature, that are not regionally, socio-economically, culturally or individually defined.

1.6 Breastfeeding
1.6.1 Mother

Include here also age at first lactation, duration of breastfeeding, number of children breast-fed

1.6.2 Child

Results concerning the effects of breastfeeding on the development of cancer should be disaggregated into effects on the mother and effects on the child. Wherever
possible detailed information on duration of total and exclusive breastfeeding, and of complementary feeding should be included.

1.7 Other issues

For example results related to diet diversity, meal frequency, frequency of snacking, dessert-eating and breakfast-eating should be reported here. Eating out of home should be reported here.

2 Foods

*2.0.1 Plant foods

2.1 Starchy foods

2.1.1 Cereals (grains)

* 2.1.1.0.1 Rice, pasta, noodles
* 2.1.1.0.2 Bread
* 2.1.1.0.3 Cereal

* Report under this subheading the cereals when it is not specified if they are wholegrain or refined cereals (e.g. fortified cereals)

2.1.1.1 Wholegrain cereals and cereal products

* 2.1.1.1.1 Wholegrain rice, pasta, noodles
* 2.1.1.1.2 Wholegrain bread
* 2.1.1.1.3 Wholegrain cereal

2.1.1.2 Refined cereals and cereal products

* 2.1.1.2.1 Refined rice, pasta, noodles
* 2.1.1.2.2 Refined bread
* 2.1.1.2.3 Refined cereal

2.1.2 Starchy roots, tubers and plantains

* 2.1.2.1 Potatoes

2.1.3 Other starchy foods

*Report polenta under this heading

2.2 Fruit and (non-starchy) vegetables

Results for “fruit and vegetables” and “fruits, vegetables and fruit juices” should be reported here. If the definition of vegetables used here is different from that used in the first report, this should be highlighted.

2.2.1 Non-starchy vegetables
This heading should be used to report total non-starchy vegetables. If results about specific vegetables are reported they should be recorded under one of the subheadings below or if not covered, they should be recorded under ‘2.2.1.5 other’.

2.2.1.1 Non-starchy root vegetables and tubers

*2.2.1.1.1 Carrots

2.2.1.2 Cruciferous vegetables
2.2.1.3 Allium vegetables
2.2.1.4 Green leafy vegetables (not including cruciferous vegetables)
2.2.1.5 Other non-starchy vegetables

*2.2.1.5.13 Tomatoes
*2.2.1.5.1 Fresh beans (e.g. string beans, French beans) and peas

Other non-starchy vegetables’ should include foods that are botanically fruits but are eaten as vegetables, e.g. courgettes. In addition vegetables such as French beans that do not fit into the other categories, above.

If there is another sub-category of vegetables that does not easily fit into a category above eg salted root vegetables (ie you do not know if it is starchy or not) then report under 2.2.1.5. and note the precise definition used by the study. If in doubt, enter the exposure more than once in this way.

2.2.1.6 Raw vegetables

This section should include any vegetables specified as eaten raw. Results concerning specific groups and type of raw vegetable should be reported twice i.e. also under the relevant headings 2.2.1.1 –2.2.1.5.

2.2.2 Fruits

*2.2.2.0.1 Fruit, dried
*2.2.2.0.2 Fruit, canned
*2.2.2.0.3 Fruit, cooked

2.2.2.1 Citrus fruit

2.2.2.1.1 Oranges
2.2.2.1.2 Other citrus fruits (e.g. grapefruits)

2.2.2.2 Other fruits

*2.2.2.2.1 Bananas
*2.2.2.2.4 Melon
*2.2.2.2.5 Papaya
*2.2.2.2.7 Blueberries, strawberries and other berries
*2.2.2.2.8 Apples, pears
*2.2.2.2.10 Peaches, apricots, plums
*2.2.2.2.11 Grapes
If results are available that consider other groups of fruit or a particular fruit please report under ‘other’, specifying the grouping/fruit used in the literature.

2.3 Pulses (legumes)

*2.3.1 Soya, soya products
  *2.3.1.1 Miso, soya paste soup
  *2.3.1.2 Soya juice
  *2.3.1.4 Soya milk
  *2.3.1.5 Tofu

*2.3.2 Dried beans, chickpeas, lentiles
*2.3.4 Peanuts, peanut products

Where results are available for a specific pulse/legume, please report under a separate heading.

2.4 Nuts and Seeds

To include all tree nuts and seeds, but not peanuts (groundnuts). Where results are available for a specific nut/seed, e.g. brazil nuts, please report under a separate heading.

2.5 Meat, poultry, fish and eggs

Wherever possible please differentiate between farmed and wild meat, poultry and fish.

2.5.1 Meat

This heading refers only to red meat: essentially beef, lamb, pork from farmed domesticated animals either fresh or frozen, or dried without any other form of preservation. It does not refer to poultry or fish.

Where there are data for offal (organs and other non-flesh parts of meat) and also when there are data for wild and non-domesticated animals, please show these separately under this general heading as a subcategory.

2.5.1.1 Fresh Meat
2.5.1.2 Processed meat
  *2.5.1.2.1 Ham
  *2.5.1.2.1.7 Burgers
  *2.5.1.2.8 Bacon
  *2.5.1.2.9 Hot dogs
  *2.5.1.2.10 Sausages

Repeat results concerning processed meat here and under the relevant section under 4. Food Production and Processing. Please record the definition of ‘processed meat’ used by each study.
2.5.1.3 Red meat

*2.5.1.3.1 Beef
*2.5.1.3.2 Lamb
*2.5.1.3.3 Pork
*2.5.1.3.6 Horse, rabbit, wild meat (game)

Where results are available for a particular type of meat, e.g. beef, pork or lamb, please report under a separate heading.

Show any data on wild meat (game) under this heading as a separate sub-category.

2.5.1.4 Poultry

Show any data on wild birds under this heading as a separate sub-category.

*2.5.1.5 Offals, offal products (organ meats)

2.5.2 Fish

*2.5.2.3 Fish, processed (dried, salted, smoked)
*2.5.2.5 Fatty Fish
*2.5.2.7 Dried Fish
*2.5.2.9 White fish, lean fish

2.5.3 Shellfish and other seafood

2.5.4 Eggs

2.6 Fats, oils and sugars

2.6.1 Animal fats

*2.6.1.1 Butter
*2.6.1.2 Lard
*2.6.1.3 Gravy
*2.6.1.4 Fish oil

2.6.2 Plant oils
2.6.3 Hydrogenated fats and oils

*2.6.3.1 Margarine

Results concerning hydrogenated fats and oils should be reported twice, here and under 4.3.2 Hydrogenation

2.6.4 Sugars

This heading refers to added (extrinsic) sugars and syrups as a food, that is refined sugars, such as table sugar, or sugar used in bakery products.
2.7 Milk and dairy products

Results concerning milk should be reported twice, here and under 3.3 Milk

*2.7.1 Milk, fresh milk, dried milk
*2.7.1.1 Whole milk, full-fat milks
*2.7.1.2 Semi skimmed milk, skimmed milk, low fat milk, 2% Milk

*2.7.2 Cheese
*2.7.2.1 Cottage cheese
*2.7.2.2 Cheese, low fat

*2.7.3 Yoghurt, buttermilk, sour milk, fermented milk drinks
*2.7.3.1 Fermented whole milk
*2.7.3.2 Fermented skimmed milk

*2.7.7 Ice cream

2.8 Herbs, spices, condiments

*2.8.1 Ginseng
*2.8.2 Chili pepper, green chili pepper, red chili pepper

2.9 Composite foods

Eg, snacks, crisps, desserts, pizza. Also report any mixed food exposures here ie if an exposure is reported as a combination of 2 or more foods that cross categories (eg bacon and eggs). Label each mixed food exposure.

*2.9.1 Cakes, biscuits and pastry
*2.9.2 Cookies
*2.9.3 Confectionery
*2.9.4 Soups
*2.9.5 Pizza
*2.9.6 Chocolate, candy bars
*2.9.7 Snacks

3 Beverages

3.1 Total fluid intake

3.2 Water

3.3 Milk

For results concerning milk please report twice, here and under 2.7 Milk and Dairy Products.
3.4 Soft drinks

*Soft drinks that are both carbonated and sugary should be reported under this general heading. Drinks that contain artificial sweeteners should be reported separately and labelled as such.*

3.4.1 Sugary (not carbonated)
3.4.2 Carbonated (not sugary)

*The precise definition used by the studies should be highlighted, as definitions used for various soft drinks vary greatly.*

*3.5 Fruit and vegetable juices

*3.5.1 Citrus fruit juice
*3.5.2 Fruit juice
*3.5.3 Vegetable juice
*3.5.4 Tomato juice*

3.6 Hot drinks

3.6.1 Coffee
3.6.2 Tea

*Report herbal tea as a sub-category under tea.*

3.6.2.1 Black tea
3.6.2.2 Green tea
3.6.3 Maté
3.6.4 Other hot drinks

3.7 Alcoholic drinks

3.7.1 Total

3.7.1.1 Beers
3.7.1.2 Wines
3.7.1.3 Spirits
3.7.1.4 Other alcoholic drinks

4 Food production, preservation, processing and preparation

4.1 Production

4.1.1 Traditional methods *(to include ‘organic’)*
4.1.2 Chemical contaminants

*Only results based on human evidence should be reported here (see instructions for dealing with mechanistic studies). Please be comprehensive and cover the exposures listed below:*

4.1.2.1 Pesticides
4.1.2.2 DDT
4.1.2.3 Herbicides
4.1.2.4 Fertilisers
4.1.2.5 Veterinary drugs
4.1.2.6 Other chemicals

4.1.2.6.1 Polychlorinated dibenzofurans (PCDFs)
4.1.2.6.2 Polychlorinated dibenzodioxins (PCDDs)
4.1.2.6.3 Polychlorinated biphenyls (PCBs)

4.1.2.7 Heavy metals

4.1.2.7.1 Cadmium
4.1.2.7.2 Arsenic

4.1.2.8 Waterborne residues

4.1.2.8.1 Chlorinated hydrocarbons

4.1.2.9 Other contaminants

Please also report any results that cover the cumulative effect of low doses of contaminants in this section.

4.2 Preservation

4.2.1 Drying

4.2.2 Storage

4.2.2.1 Mycotoxins
4.2.2.1.1 Aflatoxins
4.2.2.1.2 Others

4.2.3 Bottling, canning, vacuum packing
4.2.4 Refrigeration
4.2.5 Salt, salting

4.2.5.1 Salt
4.2.5.2 Salting
4.2.5.3 Salted foods

4.2.5.3.1 Salted animal food
4.2.5.3.2 Salted plant food

4.2.6 Pickling
4.2.7 Curing and smoking

4.2.7.1 Cured foods

4.2.7.1.1 Cured meats
4.2.7.1.2 Smoked foods
For some cancers e.g. colon, rectum, oesophageal and pancreas, it may be important to report results about specific cured foods, cured meats and smoked meats. N-nitrososamines should also be covered here.

4.3 Processing

4.3.1 Refining

Results concerning refined cereals and cereal products should be reported twice, here and under 2.1.1.2 refined cereals and cereal products.

4.3.2 Hydrogenation

Results concerning hydrogenated fats and oils should be reported twice, here and under 2.6.3 Hydrogenated fats and oils

4.3.3 Fermenting

4.3.4 Compositional manipulation

4.3.4.1 Fortification
4.3.4.2 Genetic modification
4.3.4.3 Other methods

4.3.5 Food additives

4.3.5.1 Flavours

Report results for monosodium glutamate as a separate category under 4.3.5.1 Flavours.

4.3.5.2 Sweeteners (non-caloric)
4.3.5.3 Colours
4.3.5.4 Preservatives

4.3.5.4.1 Nitrites and nitrates

4.3.5.5 Solvents
4.3.5.6 Fat substitutes
4.3.5.7 Other food additives

Please also report any results that cover the cumulative effect of low doses of additives. Please also report any results that cover synthetic antioxidants

4.3.6 Packaging

4.3.6.1 Vinyl chloride
4.3.6.2 Phthalates

4.4 Preparation

4.4.1 Fresh food
4.4.1.1 Raw

Report results regarding all raw food other than fruit and vegetables here. There is a separate heading for raw fruit and vegetables (2.2.1.6).

4.4.1.2 Juiced

4.4.2 Cooked food

4.4.2.1 Steaming, boiling, poaching
4.4.2.2 Stewing, casseroling
4.4.2.3 Baking, roasting
4.4.2.4 Microwaving
4.4.2.5 Frying
4.4.2.6 Grilling (broiling) and barbecuing
4.4.2.7 Heating, re-heating

Some studies may have reported methods of cooking in terms of temperature or cooking medium, and also some studies may have indicated whether the food was cooked in a direct or indirect flame. When this information is available, it should be included in the SLR report.

Results linked to mechanisms e.g. heterocyclic amines, acrylamides and polycyclic aromatic hydrocarbons should also be reported here. There may also be some literature on burned food that should be reported in this section.

1 5 Dietary constituents

Food constituents' relationship to outcome needs to be considered in relation to dose and form including use in fortified foods, food supplements, nutrient supplements and specially formulated foods. Where relevant and possible these should be disaggregated.

5.1 Carbohydrate

5.1.1 Total carbohydrate
5.1.2 Non-starch polysaccharides/dietary fibre

5.1.2.1 Cereal fibre
5.1.2.2 Vegetable fibre
5.1.2.3 Fruit fibre

5.1.3 Starch

5.1.3.1 Resistant starch

5.1.4 Sugars
*5.1.5 Glycemic index, glycemic load

This heading refers to intrinsic sugars that are naturally incorporated into the cellular structure of foods, and also extrinsic sugars not incorporated into the cellular
structure of foods. Results for intrinsic and extrinsic sugars should be presented separately. Count honey and sugars in fruit juices as extrinsic. They can be natural and unprocessed, such as honey, or refined such as table sugar. Any results related to specific sugars e.g. fructose should be reported here.

5.2 Lipids

5.2.1 Total fat
5.2.2 Saturated fatty acids
5.2.3 Monounsaturated fatty acids
5.2.4 Polyunsaturated fatty acids

5.2.4.1 n-3 fatty acids

Where available, results concerning alpha linolenic acid and long chain n-3 PUFA should be reported here, and if possible separately.

5.2.4.2 n-6 fatty acids
5.2.4.3 Conjugated linoleic acid

5.2.5 Trans fatty acids
5.2.6 Other dietary lipids, cholesterol, plant sterols and stanols.

For certain cancers, e.g. endometrium, lung, and pancreas, results concerning dietary cholesterol may be available. These results should be reported under this section.

5.3 Protein

5.3.1 Total protein
5.3.2 Plant protein
5.3.3 Animal protein

5.4 Alcohol

This section refers to ethanol the chemical. Results related to specific alcoholic drinks should be reported under 3.7 Alcoholic drinks. Past alcohol refers, for example, to intake at age 18, during adolescence, etc.

*5.4.1 Total Alcohol (as ethanol)

*5.4.1.1 Alcohol (as ethanol) from beer
*5.4.1.2 Alcohol (as ethanol) from wine
*5.4.1.3 Alcohol (as ethanol) from spirits
*5.4.1.4 Alcohol (as ethanol) from other alcoholic drinks
* 5.4.1.5 Total alcohol (as ethanol), lifetime exposure

* 5.4.1.6 Total alcohol (as ethanol), past

5.5 Vitamins

*5.5.0 Vitamin supplements
5.5.0.1 Vitamin and mineral supplements
5.5.0.2 Vitamin B supplement

5.5.1 Vitamin A

5.5.1.1 Retinol
5.5.1.2 Provitamin A carotenoids

5.5.2 Non-provitamin A carotenoids

Record total carotenoids under 5.5.2 as a separate category marked Total Carotenoids.

5.5.3 Folates and associated compounds

*5.5.3.1 Total folate
*5.5.3.2 Dietary folate
*5.5.3.3 Folate from supplements

Examples of the associated compounds are lipotropes, methionine and other methyl donors.

5.5.4 Riboflavin
5.5.5 Thiamin (vitamin B1)
5.5.6 Niacin
5.5.7 Pyridoxine (vitamin B6)
5.5.8 Cobalamin (vitamin B12)
5.5.9 Vitamin C
5.5.10 Vitamin D (and calcium)
5.5.11 Vitamin E
5.5.12 Vitamin K
5.5.13 Other

If results are available concerning any other vitamins not listed here, then these should be reported at the end of this section. In addition, where information is available concerning multiple vitamin deficiencies, these should be reported at the end of this section under ‘other’.

5.6 Minerals

5.6.1 Sodium
5.6.2 Iron
5.6.3 Calcium (and Vitamin D)
5.6.4 Selenium
5.6.5 Iodine
5.6.6 Other

Results are likely to be available on other minerals e.g. magnesium, potassium, zinc, copper, phosphorus, manganese and chromium for certain cancers. These should be reported at the end of this section when appropriate under ‘other’.

5.7 Phytochemicals
5.7.1 Allium compounds
5.7.2 Isothiocyanates
5.7.3 Glucosinolates and indoles
5.7.4 Polyphenols
5.7.5 Phytoestrogens eg genistein
5.7.6 Caffeine
5.7.7 Other

Where available report results relating to other phytochemicals such as saponins and coumarins. Results concerning any other bioactive compounds, which are not phytochemicals should be reported under the separate heading 'other bioactive compounds'. Eg flavonoids, isoflavonoids, glycoalkaloids, cyanogens, oligosaccharides and anthocyanins should be reported separately under this heading.

5.8 Other bioactive compounds

6 Physical activity

6.1 Total physical activity (overall summary measures)

6.1.1 Type of activity

6.1.1.1 Occupational
6.1.1.2 Recreational
6.1.1.3 Household
6.1.1.4 Transportation

6.1.2 Frequency of physical activity

*6.1.2.1 Frequency of occupational physical activity
*6.1.2.2 Frequency of recreational physical activity

6.1.3 Intensity of physical activity

*6.1.3.1 Intensity of occupational physical activity
*6.1.3.2 Intensity of recreational physical activity

6.1.4 Duration of physical activity

*6.1.4.1 Duration of occupational physical activity
*6.1.4.2 Duration of recreational physical activity

6.2 Physical inactivity

6.3 Surrogate markers for physical activity e.g. occupation

7 Energy balance

7.1 Energy intake

*7.1.0.1 Energy from fats
*7.1.0.2 Energy from protein
*7.1.0.3 Energy from carbohydrates
*7.1.0.4 Energy from alcohol
7.1.0.5 Energy from all other sources

7.1.1 Energy density of diet

7.2 Energy expenditure

1.1.1 8 Anthropometry

8.1 Markers of body composition

8.1.1 BMI
8.1.2 Other weight adjusted for height measures
8.1.3 Weight
8.1.4 Skinfold measurements
8.1.5 Other (e.g. DEXA, bio- impedance, etc)
8.1.6 Change in body composition (including weight gain)

8.2 Markers of distribution of fat

8.2.1 Waist circumference
8.2.2 Hips circumference
8.2.3 Waist to hip ratio
8.2.4 Skinfolds ratio
8.2.5 Other e.g. CT, ultrasound

8.3 Skeletal size

8.3.1 Height (and proxy measures)
8.3.2 Other (e.g. leg length)

8.4 Growth in fetal life, infancy or childhood

8.4.1 Birthweight,
8.4.2 Weight at one year